Hutchmed China inks USD1.30 billion GSK deal for cancer drug HMPL-A830
Hutchmed China PLC on Thursday announced that its subsidiary, Hutchmed Ltd, has entered into an exclusive development licence agreement with a subsidiary of GSK PLC.
The Hong Kong-based biopharmaceutical company said the agreement grants GSK worldwide rights, excluding China, Hong Kong, Macau and Taiwan, to commercialise the antibody-drug conjugate HMPL-A830.
HMPL-A830, currently in development, targets cancers with KRAS gene mutations, which are common in colorectal, lung and pancreatic cancers, and has the potential to improve the efficacy and durability of treatment.
An upfront payment of USD110 million was agreed for the cancer therapy deal, which includes milestone and royalty payments of up to USD1.30 billion, Hutchmed China said.
Under the agreement, Hutchmed Ltd will develop the global phase 1 programme, which is expected to start in the second half of 2026, Hutchmed China said.
Hutchmed China Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng highlighted the company’s innovative ATTC platform, which combines antibodies with proprietary payloads to deliver dual mechanisms of action. He said the licensing of HMPL-A830 to GSK marks a major milestone for Hutchmed and could help unlock a new class of precision oncology medicines.
GSK Senior Vice President Hesham Abdullah said the agreement reflects GSK’s growing leadership in oncology and the company’s commitment to advancing the latest innovations for cancer patients.
"The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care. We look forward to working with HUTCHMED to progress this innovative asset through development," Abdullah said.
Shares in Hutchmed China soared 16% to 207.57 pence per share on Thursday morning in London, while GSK shares were up 0.4% at 1,869.00 pence per share.
Copyright 2026 Alliance News Ltd. All Rights Reserved.